THX 110

Drug Profile

THX 110

Alternative Names: THX OSA01; THX RS01; THX-110; THX-TS01

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Therapix Biosciences
  • Class Cannabinoids; Ethanolamines; Neuropsychotherapeutics; Non-opioid analgesics; Palmitic acids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome
  • Phase II Sleep apnoea syndrome

Most Recent Events

  • 09 Nov 2017 Phase-II clinical trials in Sleep apnoea syndrome in Israel (unspecified route)
  • 09 Nov 2017 Therapix Biosciences announces intention to submit an Investigational Medicinal Product Dossier in Germany for a phase IIb trial for Gilles de la Tourette's syndrome in late 2017
  • 09 Nov 2017 Therapix Biosciences and Hannover Medical School plan a phase IIb trial for Tourette Syndrome in Germany
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top